

Table 1.17

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity

Both Sexes, Total U.S., 2014-2016

Site	All Races	Whites	Blacks
	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
All Sites	19.71 (19.69, 19.74)	19.85 (19.83, 19.88)	19.71 (19.63, 19.80)
Oral Cavity and Pharynx	0.30 (0.30, 0.30)	0.30 (0.30, 0.31)	0.27 (0.26, 0.28)
Esophagus	0.47 (0.47, 0.47)	0.50 (0.50, 0.51)	0.33 (0.31, 0.34)
Stomach	0.37 (0.37, 0.38)	0.32 (0.32, 0.33)	0.60 (0.58, 0.61)
Colon and Rectum	1.75 (1.74, 1.76)	1.72 (1.71, 1.73)	2.03 (2.00, 2.06)
Liver and Intrahepatic Bile Duct	0.77 (0.77, 0.78)	0.73 (0.72, 0.74)	0.87 (0.85, 0.88)
Pancreas	1.37 (1.36, 1.38)	1.37 (1.36, 1.38)	1.45 (1.43, 1.48)
Larynx	0.12 (0.11, 0.12)	0.11 (0.11, 0.11)	0.16 (0.15, 0.17)
Lung and Bronchus	4.97 (4.95, 4.98)	5.08 (5.07, 5.10)	4.54 (4.49, 4.58)
Melanoma of the Skin	0.29 (0.28, 0.29)	0.33 (0.33, 0.33)	0.04 (0.03, 0.04)
Breast	1.34 (1.33, 1.35)	1.31 (1.30, 1.32)	1.67 (1.65, 1.70)
Urinary Bladder	0.62 (0.61, 0.62)	0.65 (0.64, 0.66)	0.43 (0.41, 0.44)
Kidney and Renal Pelvis	0.46 (0.46, 0.46)	0.47 (0.47, 0.48)	0.39 (0.38, 0.41)
Brain and Other Nervous System	0.47 (0.47, 0.48)	0.52 (0.51, 0.52)	0.26 (0.25, 0.27)
Thyroid	0.06 (0.06, 0.07)	0.06 (0.06, 0.07)	0.06 (0.05, 0.06)
Hodgkin Lymphoma	0.03 (0.03, 0.03)	0.03 (0.03, 0.04)	0.02 (0.02, 0.03)
Non-Hodgkin Lymphoma	0.72 (0.71, 0.72)	0.75 (0.75, 0.76)	0.42 (0.41, 0.44)
Myeloma	0.42 (0.42, 0.43)	0.40 (0.39, 0.40)	0.69 (0.67, 0.71)
Leukemia	0.82 (0.81, 0.82)	0.85 (0.85, 0.86)	0.58 (0.56, 0.60)
Acute Lymphocytic Leukemia	0.04 (0.04, 0.04)	0.04 (0.04, 0.05)	0.03 (0.02, 0.03)
Chronic Lymphocytic Leukemia	0.17 (0.17, 0.18)	0.18 (0.18, 0.19)	0.11 (0.11, 0.12)
Acute Myeloid Leukemia	0.33 (0.33, 0.34)	0.35 (0.35, 0.35)	0.23 (0.22, 0.24)
Chronic Myeloid Leukemia	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	0.03 (0.03, 0.03)

Devcan Version 6.7.7, April 2019, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: NCHS public use data file for the total US.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.17 - continued

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity

Both Sexes, Total U.S., 2014-2016

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives ^a	Hispanics ^b
	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
All Sites	17.87 (17.67, 18.07)	15.99 (15.57, 16.43)	17.13 (17.00, 17.25)
Oral Cavity and Pharynx	0.33 (0.30, 0.36)	0.27 (0.21, 0.35)	0.24 (0.22, 0.25)
Esophagus	0.26 (0.24, 0.29)	0.38 (0.32, 0.48)	0.30 (0.29, 0.32)
Stomach	0.99 (0.94, 1.04)	0.52 (0.44, 0.62)	0.73 (0.70, 0.75)
Colon and Rectum	1.81 (1.74, 1.89)	1.65 (1.51, 1.82)	1.73 (1.69, 1.77)
Liver and Intrahepatic Bile Duct	1.49 (1.43, 1.54)	1.09 (0.99, 1.22)	1.30 (1.27, 1.34)
Pancreas	1.43 (1.37, 1.50)	1.01 (0.90, 1.15)	1.29 (1.26, 1.33)
Larynx	0.06 (0.04, 0.07)	0.09 (0.06, 0.15)	0.10 (0.09, 0.11)
Lung and Bronchus	4.06 (3.96, 4.16)	3.67 (3.46, 3.89)	2.77 (2.72, 2.83)
Melanoma of the Skin	0.06 (0.05, 0.08)	0.07 (0.05, 0.14)	0.11 (0.09, 0.12)
Breast	0.96 (0.91, 1.01)	0.92 (0.80, 1.06)	1.12 (1.08, 1.15)
Urinary Bladder	0.45 (0.41, 0.50)	0.35 (0.28, 0.46)	0.44 (0.41, 0.46)
Kidney and Renal Pelvis	0.32 (0.29, 0.35)	0.58 (0.51, 0.69)	0.53 (0.50, 0.55)
Brain and Other Nervous System	0.31 (0.29, 0.34)	0.23 (0.18, 0.31)	0.37 (0.36, 0.39)
Thyroid	0.11 (0.09, 0.13)	0.04 (0.02, 0.09)	0.11 (0.10, 0.12)
Hodgkin Lymphoma	0.02 (0.02, 0.03)	0.02 (0.01, 0.08)	0.05 (0.05, 0.06)
Non-Hodgkin Lymphoma	0.72 (0.68, 0.77)	0.49 (0.42, 0.60)	0.73 (0.70, 0.76)
Myeloma	0.28 (0.26, 0.31)	0.36 (0.29, 0.46)	0.42 (0.40, 0.44)
Leukemia	0.58 (0.55, 0.62)	0.40 (0.33, 0.49)	0.66 (0.64, 0.69)
Acute Lymphocytic Leukemia	0.05 (0.04, 0.06)	0.05 (0.03, 0.11)	0.07 (0.06, 0.07)
Chronic Lymphocytic Leukemia	0.04 (0.03, 0.06)	0.03 (0.01, 0.09)	0.08 (0.07, 0.10)
Acute Myeloid Leukemia	0.31 (0.28, 0.33)	0.16 (0.12, 0.22)	0.27 (0.25, 0.28)
Chronic Myeloid Leukemia	0.03 (0.02, 0.04)	0.02 (0.01, 0.07)	0.04 (0.03, 0.05)

Devcan Version 6.7.7, April 2019, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: NCHS public use data file for the total US.

^a Underlying mortality data for American Indian/Alaska Native are based on the PRCDA (Purchased/Referred Care Delivery Areas) counties.^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.
A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.18

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity

Males, Total U.S., 2014-2016

Site	All Races	Whites	Blacks
	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
All Sites	21.34 (21.30, 21.38)	21.45 (21.40, 21.49)	21.45 (21.32, 21.59)
Oral Cavity and Pharynx	0.42 (0.41, 0.43)	0.42 (0.41, 0.43)	0.40 (0.38, 0.42)
Esophagus	0.76 (0.75, 0.76)	0.81 (0.80, 0.82)	0.48 (0.46, 0.50)
Stomach	0.45 (0.44, 0.45)	0.39 (0.38, 0.40)	0.75 (0.72, 0.78)
Colon and Rectum	1.83 (1.82, 1.85)	1.80 (1.78, 1.81)	2.14 (2.09, 2.19)
Liver and Intrahepatic Bile Duct	1.02 (1.01, 1.03)	0.95 (0.94, 0.96)	1.20 (1.17, 1.23)
Pancreas	1.39 (1.38, 1.40)	1.40 (1.39, 1.42)	1.37 (1.34, 1.41)
Larynx	0.19 (0.18, 0.19)	0.18 (0.18, 0.19)	0.28 (0.27, 0.30)
Lung and Bronchus	5.49 (5.47, 5.51)	5.54 (5.52, 5.56)	5.45 (5.39, 5.53)
Melanoma of the Skin	0.39 (0.38, 0.40)	0.45 (0.44, 0.45)	0.04 (0.03, 0.05)
Breast	0.03 (0.03, 0.03)	0.03 (0.03, 0.03)	0.05 (0.04, 0.06)
Prostate	2.44 (2.42, 2.46)	2.29 (2.28, 2.31)	3.94 (3.87, 4.02)
Testis	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.01 (0.01, 0.02)
Urinary Bladder	0.93 (0.92, 0.95)	0.99 (0.98, 1.00)	0.54 (0.51, 0.57)
Kidney and Renal Pelvis	0.60 (0.60, 0.61)	0.62 (0.61, 0.63)	0.51 (0.49, 0.54)
Brain and Other Nervous System	0.53 (0.53, 0.54)	0.58 (0.57, 0.59)	0.28 (0.26, 0.29)
Thyroid	0.06 (0.06, 0.06)	0.06 (0.06, 0.06)	0.04 (0.03, 0.04)
Hodgkin Lymphoma	0.04 (0.04, 0.04)	0.04 (0.04, 0.04)	0.03 (0.02, 0.04)
Non-Hodgkin Lymphoma	0.81 (0.80, 0.82)	0.85 (0.84, 0.86)	0.46 (0.44, 0.48)
Myeloma	0.47 (0.47, 0.48)	0.45 (0.45, 0.46)	0.70 (0.67, 0.73)
Leukemia	0.96 (0.95, 0.97)	1.01 (1.00, 1.02)	0.65 (0.62, 0.67)
Acute Lymphocytic Leukemia	0.05 (0.05, 0.05)	0.05 (0.05, 0.05)	0.03 (0.02, 0.03)
Chronic Lymphocytic Leukemia	0.21 (0.21, 0.22)	0.22 (0.22, 0.23)	0.14 (0.13, 0.15)
Acute Myeloid Leukemia	0.39 (0.38, 0.40)	0.41 (0.40, 0.42)	0.25 (0.23, 0.26)
Chronic Myeloid Leukemia	0.05 (0.04, 0.05)	0.05 (0.05, 0.05)	0.03 (0.03, 0.04)

Devcan Version 6.7.7, April 2019, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).
Source: NCHS public use data file for the total US.
A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.18 - continued

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity

Males, Total U.S., 2014-2016

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives ^a	Hispanics ^b
	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
All Sites	20.17 (19.85, 20.50)	16.97 (16.36, 17.64)	19.33 (19.12, 19.53)
Oral Cavity and Pharynx	0.46 (0.42, 0.52)	0.36 (0.28, 0.53)	0.33 (0.30, 0.36)
Esophagus	0.41 (0.37, 0.47)	0.64 (0.52, 0.83)	0.50 (0.46, 0.53)
Stomach	1.16 (1.08, 1.26)	0.60 (0.49, 0.79)	0.84 (0.79, 0.89)
Colon and Rectum	1.89 (1.78, 2.00)	1.83 (1.63, 2.10)	1.95 (1.88, 2.02)
Liver and Intrahepatic Bile Duct	1.99 (1.90, 2.08)	1.32 (1.17, 1.54)	1.66 (1.61, 1.72)
Pancreas	1.41 (1.32, 1.51)	0.96 (0.82, 1.18)	1.29 (1.24, 1.35)
Larynx	0.10 (0.08, 0.13)	0.17 (0.12, 0.33)	0.20 (0.18, 0.22)
Lung and Bronchus	5.02 (4.86, 5.19)	3.90 (3.59, 4.27)	3.45 (3.36, 3.54)
Melanoma of the Skin	0.06 (0.04, 0.09)	0.10 (0.05, 0.25)	0.13 (0.11, 0.16)
Breast	0.02 (0.01, 0.05)	0.00 (0.00, 0.15)	0.02 (0.02, 0.04)
Prostate	2.18 (2.04, 2.33)	2.20 (1.91, 2.56)	2.76 (2.66, 2.86)
Testis	0.01 (0.00, 0.03)	0.03 (0.02, 0.18)	0.03 (0.02, 0.04)
Urinary Bladder	0.73 (0.65, 0.83)	0.44 (0.33, 0.63)	0.65 (0.60, 0.70)
Kidney and Renal Pelvis	0.44 (0.39, 0.49)	0.75 (0.63, 0.95)	0.69 (0.65, 0.74)
Brain and Other Nervous System	0.32 (0.29, 0.37)	0.22 (0.16, 0.37)	0.41 (0.38, 0.44)
Thyroid	0.08 (0.06, 0.11)	0.04 (0.02, 0.19)	0.08 (0.07, 0.09)
Hodgkin Lymphoma	0.03 (0.02, 0.05)	0.02 (0.01, 0.17)	0.06 (0.05, 0.07)
Non-Hodgkin Lymphoma	0.85 (0.78, 0.93)	0.57 (0.44, 0.78)	0.83 (0.78, 0.88)
Myeloma	0.31 (0.28, 0.36)	0.35 (0.24, 0.55)	0.47 (0.45, 0.51)
Leukemia	0.72 (0.66, 0.78)	0.48 (0.39, 0.66)	0.80 (0.75, 0.85)
Acute Lymphocytic Leukemia	0.04 (0.03, 0.06)	0.04 (0.02, 0.19)	0.07 (0.06, 0.09)
Chronic Lymphocytic Leukemia	0.06 (0.04, 0.08)	0.03 (0.01, 0.18)	0.11 (0.09, 0.14)
Acute Myeloid Leukemia	0.38 (0.34, 0.43)	0.19 (0.13, 0.34)	0.31 (0.29, 0.34)
Chronic Myeloid Leukemia	0.03 (0.02, 0.06)	0.03 (0.01, 0.18)	0.06 (0.05, 0.08)

Devcan Version 6.7.7, April 2019, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: NCHS public use data file for the total US.

^a Underlying mortality data for American Indian/Alaska Native are based on the PRCDA (Purchased/Referred Care Delivery Areas) counties.^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.
A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.19

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity
Females, Total U.S., 2014-2016

Site	All Races	Whites	Blacks
	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
All Sites	18.37 (18.33, 18.41)	18.52 (18.48, 18.56)	18.48 (18.37, 18.60)
Oral Cavity and Pharynx	0.19 (0.18, 0.19)	0.19 (0.18, 0.19)	0.15 (0.14, 0.16)
Esophagus	0.20 (0.20, 0.20)	0.20 (0.20, 0.21)	0.19 (0.18, 0.21)
Stomach	0.30 (0.30, 0.31)	0.26 (0.26, 0.27)	0.47 (0.45, 0.49)
Colon and Rectum	1.68 (1.67, 1.69)	1.65 (1.63, 1.66)	1.94 (1.90, 1.98)
Liver and Intrahepatic Bile Duct	0.54 (0.53, 0.54)	0.51 (0.50, 0.52)	0.57 (0.55, 0.59)
Pancreas	1.35 (1.34, 1.36)	1.34 (1.32, 1.35)	1.52 (1.48, 1.56)
Larynx	0.05 (0.04, 0.05)	0.05 (0.04, 0.05)	0.06 (0.05, 0.07)
Lung and Bronchus	4.50 (4.48, 4.52)	4.67 (4.65, 4.69)	3.77 (3.71, 3.82)
Melanoma of the Skin	0.19 (0.19, 0.20)	0.22 (0.22, 0.23)	0.04 (0.03, 0.04)
Breast	2.57 (2.55, 2.58)	2.53 (2.52, 2.55)	3.08 (3.03, 3.13)
Cervix Uteri	0.22 (0.22, 0.22)	0.21 (0.20, 0.21)	0.33 (0.32, 0.35)
Corpus and Uterus, NOS	0.63 (0.62, 0.63)	0.58 (0.58, 0.59)	1.01 (0.98, 1.04)
Ovary	0.88 (0.87, 0.89)	0.91 (0.91, 0.92)	0.70 (0.68, 0.73)
Urinary Bladder	0.35 (0.34, 0.35)	0.35 (0.34, 0.36)	0.34 (0.32, 0.36)
Kidney and Renal Pelvis	0.33 (0.32, 0.33)	0.34 (0.33, 0.34)	0.29 (0.28, 0.31)
Brain and Other Nervous System	0.42 (0.41, 0.43)	0.46 (0.45, 0.46)	0.24 (0.23, 0.25)
Thyroid	0.07 (0.07, 0.07)	0.07 (0.07, 0.07)	0.08 (0.07, 0.09)
Hodgkin Lymphoma	0.03 (0.03, 0.03)	0.03 (0.03, 0.03)	0.02 (0.02, 0.03)
Non-Hodgkin Lymphoma	0.64 (0.63, 0.65)	0.67 (0.66, 0.68)	0.40 (0.38, 0.42)
Myeloma	0.38 (0.37, 0.39)	0.35 (0.34, 0.35)	0.68 (0.66, 0.71)
Leukemia	0.68 (0.68, 0.69)	0.71 (0.70, 0.72)	0.53 (0.51, 0.55)
Acute Lymphocytic Leukemia	0.04 (0.03, 0.04)	0.04 (0.04, 0.04)	0.03 (0.02, 0.03)
Chronic Lymphocytic Leukemia	0.14 (0.13, 0.14)	0.15 (0.14, 0.15)	0.10 (0.09, 0.11)
Acute Myeloid Leukemia	0.28 (0.28, 0.29)	0.30 (0.29, 0.30)	0.21 (0.20, 0.22)
Chronic Myeloid Leukemia	0.03 (0.03, 0.04)	0.04 (0.03, 0.04)	0.03 (0.02, 0.03)

Devcan Version 6.7.7, April 2019, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).
Source: NCHS public use data file for the total US.
A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.19 - continued

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity

Females, Total U.S., 2014-2016

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives ^a	Hispanics ^b
	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
All Sites	16.14 (15.88, 16.40)	15.12 (14.54, 15.75)	15.51 (15.34, 15.67)
Oral Cavity and Pharynx	0.22 (0.19, 0.26)	0.17 (0.10, 0.30)	0.15 (0.14, 0.18)
Esophagus	0.13 (0.11, 0.16)	0.14 (0.09, 0.26)	0.14 (0.12, 0.16)
Stomach	0.85 (0.78, 0.92)	0.43 (0.33, 0.59)	0.64 (0.60, 0.67)
Colon and Rectum	1.75 (1.65, 1.85)	1.49 (1.30, 1.72)	1.55 (1.49, 1.61)
Liver and Intrahepatic Bile Duct	1.08 (1.01, 1.15)	0.87 (0.73, 1.06)	0.98 (0.94, 1.03)
Pancreas	1.46 (1.37, 1.54)	1.06 (0.88, 1.28)	1.30 (1.26, 1.35)
Larynx	0.02 (0.01, 0.04)	0.01 (0.00, 0.11)	0.02 (0.01, 0.03)
Lung and Bronchus	3.30 (3.18, 3.42)	3.47 (3.20, 3.79)	2.22 (2.16, 2.29)
Melanoma of the Skin	0.07 (0.05, 0.09)	0.05 (0.02, 0.16)	0.08 (0.07, 0.10)
Breast	1.73 (1.65, 1.82)	1.79 (1.57, 2.06)	2.07 (2.01, 2.14)
Cervix Uteri	0.23 (0.20, 0.26)	0.23 (0.17, 0.34)	0.30 (0.28, 0.33)
Corpus and Uterus, NOS	0.47 (0.43, 0.51)	0.39 (0.29, 0.54)	0.57 (0.54, 0.60)
Ovary	0.68 (0.63, 0.73)	0.73 (0.61, 0.90)	0.74 (0.71, 0.78)
Urinary Bladder	0.24 (0.21, 0.29)	0.27 (0.18, 0.43)	0.28 (0.25, 0.30)
Kidney and Renal Pelvis	0.22 (0.19, 0.26)	0.42 (0.33, 0.57)	0.39 (0.36, 0.42)
Brain and Other Nervous System	0.30 (0.27, 0.34)	0.24 (0.17, 0.37)	0.35 (0.32, 0.37)
Thyroid	0.13 (0.11, 0.16)	0.03 (0.01, 0.13)	0.13 (0.11, 0.15)
Hodgkin Lymphoma	0.02 (0.01, 0.04)	0.02 (0.00, 0.12)	0.05 (0.04, 0.06)
Non-Hodgkin Lymphoma	0.63 (0.57, 0.68)	0.43 (0.33, 0.58)	0.65 (0.62, 0.69)
Myeloma	0.25 (0.22, 0.29)	0.38 (0.29, 0.53)	0.38 (0.35, 0.40)
Leukemia	0.48 (0.43, 0.53)	0.31 (0.23, 0.45)	0.56 (0.53, 0.59)
Acute Lymphocytic Leukemia	0.05 (0.03, 0.08)	0.06 (0.03, 0.15)	0.06 (0.05, 0.07)
Chronic Lymphocytic Leukemia	0.03 (0.02, 0.05)	0.03 (0.01, 0.14)	0.06 (0.05, 0.07)
Acute Myeloid Leukemia	0.25 (0.22, 0.29)	0.12 (0.08, 0.23)	0.23 (0.21, 0.25)
Chronic Myeloid Leukemia	0.02 (0.01, 0.04)	0.01 (0.00, 0.11)	0.02 (0.02, 0.03)

Devcan Version 6.7.7, April 2019, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: NCHS public use data file for the total US.

^a Underlying mortality data for American Indian/Alaska Native are based on the PRCDA (Purchased/Referred Care Delivery Areas) counties.^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.
A percent or confidence interval value of 0.00 represents a value that is below 0.005.